U.S. markets open in 6 hours 3 minutes
  • S&P Futures

    3,381.75
    +29.75 (+0.89%)
     
  • Dow Futures

    27,944.00
    +280.00 (+1.01%)
     
  • Nasdaq Futures

    11,495.25
    +88.00 (+0.77%)
     
  • Russell 2000 Futures

    1,520.80
    +16.40 (+1.09%)
     
  • Crude Oil

    40.24
    +0.02 (+0.05%)
     
  • Gold

    1,903.30
    +7.80 (+0.41%)
     
  • Silver

    23.89
    +0.39 (+1.66%)
     
  • EUR/USD

    1.1745
    +0.0019 (+0.16%)
     
  • 10-Yr Bond

    0.6770
    0.0000 (0.00%)
     
  • Vix

    26.37
    +0.10 (+0.38%)
     
  • GBP/USD

    1.2942
    +0.0021 (+0.16%)
     
  • USD/JPY

    105.5170
    +0.0870 (+0.08%)
     
  • BTC-USD

    10,845.48
    +49.45 (+0.46%)
     
  • CMC Crypto 200

    233.70
    +12.31 (+5.56%)
     
  • FTSE 100

    5,912.48
    +46.38 (+0.79%)
     
  • Nikkei 225

    23,184.93
    -0.19 (-0.00%)
     

Aurinia Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 11, 2020

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the "Company") today announced that it will release its second quarter 2020 financial results on Tuesday, August 11, 2020, after the markets close. Aurinia’s executive team will host a conference call to discuss the Company’s financial results and to provide a general business update.

The conference call and webcast is scheduled for 4:30 pm EDT on August 11, 2020. In order to participate in the conference call, please dial +1-877-407-9170 (Toll-free U.S. & Canada). An audio webcast can be accessed under "News/Events" through the "Investors" section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.

ABOUT AURINIA

Aurinia Pharmaceuticals is a late-stage clinical biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company is currently seeking FDA approval of voclosporin for the treatment of lupus nephritis (PDUFA date: January 22, 2021) and evaluating voclosporin ophthalmic solution (VOS) in a Phase 2/3 study for the treatment of dry eye syndrome. The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub in Rockville, Maryland, and focuses its development efforts globally.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200730005288/en/

Contacts

Investor Contact:
Glenn Schulman, PharmD, MPH
SVP, Corporate Communications & IR
gschulman@auriniapharma.com